share_log

禾迈股份(688032):出货短期承压 产品拓展期研发人员大幅扩张

Hemai Co., Ltd. (688032): Short-term shipping pressure, product expansion period, significant expansion of R&D personnel

中信建投證券 ·  Sep 20, 2023 20:32

Core views

The company released its 2023 annual report. For the first half of the year, the company's revenue was 1,065 million yuan, +107.3%; net profit for the first half of the year was 348 million yuan, +72.7%; net profit after deducting non-return net profit of 332 million yuan, +72.6% year-on-year. Affected by industry inventories, the company's Q2 shipments are under slight reverse pressure. It is expected that inventory will gradually recover after consumption. Q2 The gross margin declined month-on-month, mainly due to the increase in the share of the large storage product structure of the company's expansion, while slightly inverted products still maintained high gross profit; furthermore, the company is in the new product development period, and the R&D expenses ratio has risen sharply.

occurrences

The company released its 2023 annual report. For the first half of the year, the company's revenue was 1,065 million yuan, +107.3%; net profit for the first half of the year was 348 million yuan, +72.7%; net profit after deducting non-return net profit of 332 million yuan, +72.6% year-on-year. Q2 Looking at a single quarter, the company's revenue was 485 million yuan, +70.2% year on month, -16.5% month on month; net profit of 172 million yuan, +50.3% year on year, -7.9% month on month; net profit after deducting net profit of 159 million yuan, +48.3% year on year, -2.4% month on month.

Brief review

Profitability: Q2 gross margin decreased month-on-month, R&D expense ratio increased sharply ① Gross profit margin was 42.78%, year-on-year -3.3pct, of which Q1/Q2 was 46.41%/38.43%. Gross margin fell significantly, stemming from the increase in revenue share of low-margin businesses such as large storage systems; net profit margin was 32.57%, -6.7pct, of which Q1/Q2 was 30.27%/35.44%.

② The cost rate for the company period was 11.36%, +6.3 pct, sales/management/R&D/finance expense ratio was 8.5/5.2/8.2/ -10.5%, year on year +1.1/+0.2/+2.6/+2.4 pct; during the Q1/Q2 period, the cost rate was 16.55%/5.13%, respectively. In the second quarter, the R&D expense rate increased by 4 pct and the financial expense rate decreased by 14 pct.

Performance split: Q2 slightly reversed shipping pressure

Revenue from micro-inversion and monitoring equipment was $883 million, of which 890,000 units were micro-inverse units (56/340,000 units for Q1/Q2) and 101,100 units of monitoring equipment; gross margin for Q2 is expected to remain the same month-on-month.

Expense side & inventory changes: New products expanded, R&D personnel expanded significantly ① Financial expenses: Due to fluctuations in the exchange rate of the US dollar and the euro, confirmed exchange earnings of 42.14 million yuan in the first half of the year; as well as interest income of 7146 million yuan;

② R&D expenses: R&D expenses were 86.95 million yuan, +205.4% year-on-year, mainly to meet strategic development needs such as new product development, technological innovation, and product iteration. The company introduced more R&D personnel, which led to an increase in overall remuneration, and the 2022 equity incentive plan increased the share payment expenses for R&D personnel. At the end of the reporting period, the company had 302 R&D personnel, double the number compared to the same period last year.

③ Inventory: At the end of the reporting period, the company's inventory was 818 million yuan, a slight increase from the end of the first quarter, an increase of 176 million yuan compared to the end of '22; of these, raw materials, products in stock, and goods in stock were 198, 0.64, and 405 million yuan, compared to +0.82 million, -0.28 million yuan, and +286 million yuan respectively at the end of '22.

Profit forecasts and suggestions: We expect the company's performance in 2023-2025 to be 70,120,000 yuan, and 1.75 billion yuan. The corresponding valuations are 30.1, 17.6, and 12.1X, respectively, and continue the “buy” rating.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment